The Immortality Update: Deep Research on the Most Important Discoveries and News in Longevity Sciences from the Past 7 Days (November 4–11, 2025)

I. Introduction: The Healthspan Imperative

This week's intelligence report, "The Immortality Update," analyzes a significant strategic and semantic shift in longevity science. The field is rapidly pivoting from the crude metric of *lifespan*—the total chronological duration of life—to the far more critical, functional metric of *healthspan*. This term, which defines the period of life spent in good health, free from disease and functional decline, is the exclusive focus of this report. The analysis that follows details interventions, technologies, and research published and announced between November 4 and November 11, 2025, that target the extension of a functional, vigorous, and capable life.

The emerging paradigm of 21st-century medicine is not to create frail, dependent centenarians, but to compress morbidity and extend the period of human vigor. The convergence of findings this week demonstrates that this concept has transitioned from a research buzzword to the field's primary strategic and commercial driver. This shift is not academic; it is a consensus that has permeated the entire longevity ecosystem, from commercial biopharma to top-tier academic journals and high-level policy summits.

Evidence for this consensus is threefold. First, in the commercial sphere, biopharmaceutical companies such as Vascarta Inc. now explicitly define themselves as "healthspan focused" in their public-facing announcements.[1] This is no longer a secondary benefit but a core commercial identity. Second, at the level of policy and finance, the Milken Institute Future of Health Summit, which convened this week (November 4–6, 2025) in Washington, D.C., has placed "healthy aging and longevity" as a central pillar of its agenda.[2] The inclusion of specific, high-level panels such as "The Longevity Equation: Integrating Healthspan and Wealthspan" signals that this concept is now a core strategic concern for global financial and healthcare systems.[4]

Third, and most critically, the consensus has been cemented in peer-reviewed science. The November 11, 2025, issue of the *Proceedings of the National Academy of Sciences* (*PNAS*) published research papers dedicated to the rigorous, statistical validation of "biomarkers of healthspan".[5] This convergence is not coincidental. It signifies that the field, from basic research to commercial application, has achieved agreement. The "why"—the pursuit of functional healthspan—is now settled. The remainder of this report will provide an exhaustive analysis of the "how": the specific interventions, tools, and strategies that have emerged this week to achieve it.

II. Key Findings: Novel Interventions in Cellular and Metabolic Regulation

This section details the week's most significant therapeutic breakthroughs that demonstrate a clear, mechanistic benefit to functional health. The findings are concentrated in the reprogramming of cellular function, particularly in the immune and metabolic systems.

A. Cellular Reprogramming for Glioblastoma: The STO-1 Preclinical Breakthrough

This week saw a major announcement from "healthspan focused" biopharmaceutical company Vascarta Inc. and the City University of New York (CUNY).[1] On November 10 and 11, 2025, they announced the publication of a significant preclinical study in the peer-reviewed journal *Cells*.[7] This study details a "first-in-class" drug candidate, STO-1, which offers a new therapeutic model for glioblastoma (GBM), a notoriously aggressive and fatal brain cancer that rapidly destroys functional health.

The intervention, STO-1, is a novel Taxol-derivative, engineered as a proprietary hybrid molecule that links curcumin to paclitaxel.[1] Its true innovation, however, lies not in its cytotoxic components but in its mechanism of action: *selective immune reprogramming*. Glioblastoma tumors are famously "cold," meaning they are shielded from the body's immune system. They achieve this, in part, by "hijacking" immune cells called Tumor-Associated Macrophages (TAMs) and reprogramming them into a pro-tumor, immunosuppressive M2 state.

The STO-1 study demonstrates a "Trojan Horse" strategy. The drug is designed to selectively target these "corrupted" tumor-associated cells.[1] Once inside, it flips a critical molecular

switch. The study data shows that STO-1-mediated *inhibition* of active $P\textrm{-}Tyr^{705}\textrm{-}STAT3$ and simultaneous *induction* of active $P\textrm{-}Tyr^{701}\textrm{-}STAT1$ forces a functional repolarization of the TAMs.[12] This intervention re-educates the corrupted cells, forcing them to revert from their pro-tumor M2 state to the anti-tumor, inflammatory M1 state.[12]

The functional benefit observed in the GBM mouse model was profound. Mice treated with STO-1 demonstrated a **67% long-term survival rate**, with several animals achieving **complete tumor clearance**.[1] In stark contrast, all control mice in the vehicle- and paclitaxel-treated groups succumbed to their tumors.[12] This represents a 100% functional cure in the surviving cohort of a universally fatal cancer model.

The healthspan significance of this finding is its safety profile. The therapy was shown to work **"without triggering autoimmune reactions"**.[1] Traditional cancer therapies, such as chemotherapy and radiation, operate as a bargain, sacrificing systemic healthspan and causing massive collateral damage to destroy a pathology. STO-1 demonstrates a new model: it *restores* the proper function of the immune system *only* within the pathological microenvironment, leaving the host's healthy immune function intact. This is a pure healthspan intervention, not just a cancer treatment. The platform's potential for "inflammaging"—the chronic, low-grade inflammation driven by dysfunctional macrophages that is a hallmark of aging—is immense. This selective reprogramming strategy could theoretically be applied to re-educate dysfunctional immune cells in atherosclerosis, osteoarthritis, or neurodegeneration.

B. Advancements in Solid Tumor Cellular Therapy: The ESMA CAR T-cell Platform

A second major finding in cellular reprogramming was highlighted in an editorial published on November 9, 2025, in the *International Journal of Molecular Sciences*.[15] The editorial introduces a new study on a groundbreaking cellular therapy platform: **"Novel endogenous signalling molecule activating (ESMA) CAR structures"**.[15] This represents a new generation of Chimeric Antigen Receptor (CAR) T-cell therapy.

This platform's mechanism marks a fundamental paradigm shift in immunotherapy. Current CAR T-cells are "surface-level" tools; they are engineered to recognize and target *external* antigens (markers) on a cell's surface. This approach, while revolutionary for "liquid" blood cancers, has been a comprehensive failure against solid tumors, which are heterogeneous and often "hide" these external markers to evade detection.

The ESMA platform is *introspective*. It is engineered to recognize an *intracellular* signaling molecule that is pathologically upregulated *inside* a cell. Specifically, the ESMA CAR T-cell targets **cyclin-dependent kinase 5 (CDK5)**, a molecule that is hyper-activated *within* solid tumor cells.[15] This design completely changes the rules of engagement. It stops asking the cell "Who are you?" (via a surface antigen) and starts asking "What are you *doing*?" (via internal, pathological signaling).

This targeting of a *behavioral state* rather than a fixed *identity marker* overcomes the primary failure points of tumor heterogeneity and antigen-hiding. The functional benefits, observed in preclinical mouse models of triple-negative breast cancer (TNBC)—another notoriously "cold" and difficult-to-treat solid tumor—were "profound and sustained anti-tumor effects".[15] Even more significantly, the therapy induced an **"enhanced T cell memory phenotype"** [15], implying not just a one-time tumor clearance, but a durable, functional immunity against the cancer's return.

The healthspan significance is clear: solid tumors are the primary cancer killers in aging populations. By providing a technological key to unlock "cold" tumors, the ESMA platform is a major enabler for extending functional healthspan in the majority of cancer patients. This technology, like STO-1, must be viewed as a *platform*. The CDK5 sensor is just the first module. This architecture could be re-engineered to target other pathological *internal states*, such as the signaling pathways that define a senescent cell. This provides a clear technological blueprint for a "CAR-S" (Senolytic) cell—an intelligent cellular therapy that can police the body for any type of dysfunctional cell, not just cancer.

C. Metabolic and Neuroprotective Regulation: Klotho Gene Therapy for ALS

The third key intervention of the week focuses on a systemic master regulator. On November 11, 2025, *Longevity.Technology* reported that Klotho Neurosciences is advancing its lead program, KLTO-202.[16] This is corroborated by corporate SEC filings, which confirm program financing and timelines, with a key note due in November 2025.[17]

The intervention, KLTO-202, is a gene therapy designed to deliver and express the *Klotho* gene.[16] Klotho is perhaps the most well-known "longevity gene," acting as a systemic hormone. Its decline is a canonical hallmark of aging, and its overexpression in preclinical models has been shown to extend lifespan. It exerts pleiotropic, protective effects across the brain, kidneys, and cardiovascular system.[16] The therapy aims to restore systemic levels of this master metabolic and neuroprotective regulator.

The explicit goal of this program is what makes it a quintessential healthspan intervention. The company's stated aim for KLTO-202 in Amyotrophic Lateral Sclerosis (ALS) patients is to **"protect neurons and preserve motor function"**.[16] ALS is a disease of catastrophic *functional decline*, where a patient's body fails while their mind remains intact. A therapy that "preserves motor function" is a 100% pure healthspan intervention. It is not necessarily a "cure" for the root cause of ALS, but it *is* an intervention designed to arrest functional decline, which is the metric that defines the patient's experience of the disease.

The table below synthesizes these three key therapeutic advancements, comparing their mechanisms, models, and healthspan-specific benefits.

Table 1. Analysis of Key Therapeutic Interventions (November 4–11, 2025)

Intervention / Platform	Source / Date	Therapeutic Class	Mechanism of Action	Model System	Key Functional Benefit (Healthspan)
STO-1	Vascarta / CUNY / *Cells* (Nov 10–11) [1]	Small Molecule Hybrid (Curcumin-Paclitaxel)	Selective STAT3/1-mediated reprogramming of M2 (pro-tumor) to M1 (anti-tumor) macrophages.[12]	*In vivo* mouse, Glioblastoma (GBM).[6]	67% long-term survival and complete tumor clearance with *no* autoimmune side effects.[6]
ESMA CAR T	*Int. J. Mol. Sci.* (Nov 9) [15]	Cellular Therapy (CAR T)	Targets *intracellular* pathological signaling (CDK5 upregulation) instead of external antigens.[15]	*In vivo* mouse, Triple-Negative Breast Cancer (TNBC).[15]	Profound anti-tumor effect in "cold" solid tumors; induces T-cell *memory*, implying durable

					immunity.[15]
KLTO-202	Klotho Neurosciences / *Longevity.Technology* (Nov 11) [16]	Gene Therapy	Systemic restoration of the Klotho protein, a master regulator of neuroprotection and metabolism.[16]	Human (ALS).[16]	Primary endpoint is *neuroprotection* and *preservation of motor function*—a direct anti-frailty/functional intervention.[16]

III. Distinctions in the Research Pipeline: From Basic Science to Clinical Application

To provide strategic context, this week's findings must be categorized by their Technology Readiness Level (TRL). This section distinguishes between foundational, target-finding research and assets that are nearing human application, providing a snapshot of the entire healthspan-focused R&D pipeline.

A. Preclinical Advancements (In Vivo Models)

This category includes assets that have successfully demonstrated efficacy in mammalian models, representing a high-value inflection point for translation. The STO-1 [1] and ESMA CAR T [15] platforms define this category for the week.

These are not theoretical constructs. They have successfully demonstrated profound *in vivo* functional benefits, including tumor clearance and sustained survival, in complex disease models. This places them at a critical juncture in the translational pipeline as *validated preclinical assets*. They have cleared the high-risk hurdle of *in vivo* efficacy and are positioned for the next stage of Investigational New Drug (IND)-enabling studies. Their value lies in their de-risked status, representing tangible therapeutic platforms ready for further development

and investment.

B. Early-Stage Mechanistic Insights: The Hypothalamus as an Aging 'Hot Spot'

This category represents foundational, TRL-1 research that identifies new targets and mechanisms that will direct strategy for the next decade.

A November 6, 2025, report in *The Transmitter* highlighted new research identifying a specific brain region as a "hot spot" for age-related decline.[18] The finding was contextualized by commentary from Dr. Ashley Webb of the **Buck Institute for Research on Aging**, a premier longevity institution, lending it significant credibility.[18]

The research identifies the *hypothalamus*, specifically the region surrounding the *third ventricle*, as a "focal point that seems to change quite dramatically with age".[18] This region is a master regulator of *energy homeostasis* (metabolic regulation) for the entire body. Age-related changes in energy homeostasis are a known functional decline, and this research "puts that part of the hypothalamus as a focal point" for this dysfunction.[18]

This basic science insight is critical. It provides a *target location* (hypothalamus) and a *systemic mechanism* (metabolic dysregulation) for a core component of age-related functional decline. This finding is deeply, mechanistically linked to the Klotho gene therapy discussed in Section II.C. The hypothalamus is the body's master *hormonal* regulator; Klotho is a master *hormone* for longevity and metabolism.[16] This week's research from the Buck Institute provides the "where" (the hypothalamic hot spot) that may, in fact, be the "how" of age-related metabolic decline. It raises the critical next question for the field: Does systemic Klotho decline *cause* this hypothalamic dysfunction, or does age-related hypothalamic dysfunction *suppress* systemic Klotho expression? This convergence of basic science and a clinical-stage asset provides a much clearer picture of the "master regulator" puzzle of aging.

C. Emerging Clinical Trials: Targeting Aging Frailty

This category represents the final translational bridge, where interventions are actively being tested in humans to treat healthspan-related endpoints.

This week, the research community is monitoring the progress of **NCT03514537**, a clinical

trial discussed in a review article in *Frontiers in Aging*.[19] This is an "open trial" investigating the safety and efficacy of an *autologous preparation of hAD-MSCs* (human adipose-derived mesenchymal stem cells) for the direct treatment of **"aging frailty"**.[19]

This trial is the clinical embodiment of the report's theme. "Aging frailty" is the quintessential syndrome of functional decline—a collection of symptoms including energy loss, slowed activity, and weakness that defines the loss of healthspan. The intervention, cellular therapy, is being applied directly to this geroscience-defined endpoint.[19] The urgency of this finding is its timeline: the trial's primary completion is expected in **November 2025**.[19] This places its data readout on the immediate horizon. Its success or failure will be a significant bellwether for the entire field of geroscience, validating—or invalidating—a major therapeutic approach to improving functional life in aging humans.

IV. Enabling Technologies: New Tools for Quantifying Healthspan

An intervention is only as good as the metric used to measure it. A core challenge for the longevity field has been the lack of "rulers"—quantifiable biomarkers—to prove that an intervention is improving functional healthspan. This week, multiple peer-reviewed papers published in *PNAS* have provided a breakthrough, delivering both the conceptual validation and the technological tools to solve this problem.

A. AI-Driven Histopathology: A New Biomarker for Biological Age

A major new paper was published in *PNAS* (Vol. 122, No. 45) on November 11, 2025, by Ran Meng et al..[20] The paper's publication and its contents are corroborated by multiple sources.[23]

The technology is a new platform of **machine-learning models** trained on **histological images**—microscopic pictures of stained tissue slices—from healthy donors.[20] These AI models perform two novel and critical functions: first, they identify new, previously unknown biomarkers called **"imageQTLs"** (imageable quantitative trait loci), which are distinct, quantifiable traits derived from the *visual* data of the tissue's structure.[20] Second, the models use these imageQTLs to **accurately predict the chronological age** of the donor.[20]

The healthspan significance of this tool is massive. It represents a significant leap beyond

current DNA-methylation "aging clocks." A methylation clock provides a *systemic average* biological age from a blood draw. This AI-histology tool, because it operates on *tissue samples*, can provide a *tissue-specific functional age*. It provides the tool to answer the question: "Your systemic age is 50, but your *liver's* functional age is 65." This provides a granular, quantifiable, and *visual* biomarker of functional decline in a *specific organ*. This is the precise "ruler" that clinical trials need to prove that an intervention, such as the Klotho gene therapy [16], is not just changing a blood marker but is *functionally rejuvenating* a target organ.

B. Defining the Metric: The Search for True Healthspan Biomarkers

In the *exact same* November 11, 2025, issue of *PNAS* (Vol. 122, No. 45), a second paper by Chia-Ling Kuo et al. was published.[5] This paper provides the crucial *conceptual* validation for the entire field. Its stated purpose is clear: "Despite significant efforts to develop biomarkers of aging, few studies have focused on **biomarkers of healthspan**".[5] This paper provides the rigorous statistical and methodological framework for "healthspan" as a metric distinct from "aging."

The simultaneous publication of these two papers in *PNAS* is not an accident. It is a *deliberate editorial statement* from one of the world's premier scientific journals, signaling that the quantification of healthspan is now a validated, mainstream, and high-priority scientific endeavor. The Kuo et al. paper provides the *conceptual validation* for "healthspan" as a measurable endpoint [5], while the Meng et al. paper provides the high-tech AI *tool* to actually measure it at the tissue level.[20] This synergy provides the "hard science" validation that investors and pharmaceutical companies have been waiting for, delivering the "rulers" they need to measure efficacy and de-risk clinical trials.

C. The Psycho-Social Biomarker: Optimism and Exceptional Longevity

A third *PNAS* paper, from the November 4, 2025 issue (Vol. 122, No. 44) by Lewina O. Lee et al., provides a crucial counterweight to the purely molecular focus.[28] The study, which used two large epidemiological cohorts of men and women, found a robust association: higher **"optimism is associated with exceptional longevity"**.[28] The authors explicitly conclude that "nonbiological factors are also important" in survival.[29]

This *PNAS*-published finding challenges the purely biomedical definition of an "intervention."

The report's central theme is "interventions designed to extend functional life." This study provides hard epidemiological evidence linking a *psychological function* (optimism) to a *biological function* (exceptional longevity). This suggests that a psychological state may function as a biological master regulator on par with Klotho or the hypothalamus. It forces the question: Is this association merely correlational (optimists make better lifestyle choices), or is it *mechanistic*? Does the psychological state of optimism *itself* trigger a more favorable neuro-hormonal state—perhaps through the very hypothalamic "hot spot" identified by the Buck Institute [18]—that actively promotes healthspan? This data suggests that an "intervention" which successfully and durably *increases optimism* could be considered a valid, evidence-based "longevity intervention."

V. Ethical and Practical Considerations: From Laboratory to Society

This section analyzes the critical real-world bottlenecks—cost, equity, and scalability—that will determine whether the powerful interventions identified in Section II ever reach the public.

A. The "Healthspan vs. Wealthspan" Dilemma: Equity and Accessibility

The analysis of ethical considerations is anchored by the **Milken Institute Future of Health Summit** (November 4–6, 2025).[35] A key panel at this high-level summit was titled, **"The Longevity Equation: Integrating Healthspan and Wealthspan"**.[4]

The very existence of this panel confirms the *central ethical dilemma* of the entire longevity field. As science creates powerful, complex, and expensive interventions that extend functional health, do we risk creating a new *biological caste system*? The "Longevity Equation" panel explored this "gap between what people need and what the current system delivers," confirming that at the highest levels of policy and finance, the primary concern is that the "longevity gap" will map directly onto the existing "wealth gap".[4]

B. Scaling Advanced Therapies: The Challenge of Sustainability

A November 4, 2025, industry report from **Deloitte** on cell and gene therapies provides the *practical* basis for the *ethical* concerns at Milken.[38] The Milken Summit itself identified "cell and gene therapies" as a key topic [2], and the Deloitte report poses the key industrial question: **"Can industry leaders scale advanced therapies from niche launches to mainstream, sustainable patient care?"**.[38]

The Deloitte report analyzes the "ongoing versus resolved challenges" in manufacturing, regulation, and organizational strategy required to make these therapies accessible.[38] This practical analysis provides a direct, causal link to the ethical dilemma. The ethical problem of "Healthspan vs. Wealthspan" is not a separate philosophical issue; it is a *direct causal consequence* of the practical, economic problem of scalability.

The logic is simple and unavoidable:

1. The Deloitte report identifies "cell and gene therapies" as uniquely difficult and expensive to scale.[38]
2. The *most* powerful and promising healthspan interventions identified in this week's report—namely, the **ESMA CAR T platform** [15] and the **KLTO-202 Klotho gene therapy** [16]—are *exactly* these "advanced therapies."
3. Therefore, the interventions with the *highest potential* to extend functional healthspan are *simultaneously* the *least scalable* and *most expensive* by an order of magnitude.

This direct relationship *creates* the "Healthspan vs. Wealthspan" crisis. The central challenge for the next five years is not just *scientific* (discovering interventions) but *industrial* (making them cheap, scalable, and accessible). The analysis concludes that without solving the practical, industrial challenges identified by Deloitte, the ethical fears of the Milken summit are guaranteed to become a reality.

VI. Future Directions: The Next 5 Years in Functional Longevity

This concluding section synthesizes the week's findings to project the strategic trajectory of the field, which is moving toward integrated, systems-level solutions.

A. From Reprogramming Immunity to Systemic Rejuvenation

The preclinical platforms identified this week, STO-1 and ESMA, are currently aimed at cancer, but their *mechanisms* represent their true long-term value.

The STO-1 strategy of *selective immune-cell reprogramming* [12] is a "Trojan Horse" approach that will be applied *beyond* oncology. The next five years will likely see this platform adapted to target "inflammaging" at its source, reprogramming dysfunctional senescent-associated macrophages in joints to treat osteoarthritis or in blood vessels to treat atherosclerosis.

The ESMA platform is even more flexible. It is a "sense-and-respond" technology. The internal sensor that targets CDK5 [15] is just the first module. The next five years will almost certainly see new ESMA-CARs engineered with sensors for *other* internal pathological states. The most obvious and valuable target would be the internal signaling profile of a senescent cell. This would create a "CAR-S" (Senolytic) cell—a true "smart" senolytic that hunts and kills senescent cells with unparalleled, non-toxic precision, solving the off-target toxicity problems that plague current small-molecule senolytics.

B. A Systems-Level Approach: The "Longevity Ready" Model

The future of functional longevity will not be a single pill. This week's findings, taken in aggregate, provide a clear blueprint for the *integrated system* that is emerging. This system is being built on three distinct pillars, all of which were validated by major announcements this week:

1. **The Socio-Political Framework:** The Milken Institute's new report, **"Longevity Ready: A Systems Approach to Aging Well at Home"** [35], provides the *societal* and *economic* model for delivering healthspan interventions.
2. **The Biological Framework:** The Buck Institute's research on the hypothalamus [18] and Klotho Neurosciences' gene therapy [16] represent the *metabolic master-regulator* framework, focusing on restoring systemic, top-down biological control.
3. **The Technological Framework:** The *PNAS* papers on AI-driven histopathology [20] and healthspan biomarker validation [5] provide the *technological quantification* framework, delivering the "rulers" to measure success.

The future of healthspan is the *integration* of these three pillars. It will be a system that (1) uses AI-driven biomarkers to *quantify* tissue-specific functional decline, (2) *intervenes* with systemic master-regulators (like Klotho) and precise cellular reprogramming tools (like STO-1 and ESMA), and (3) is *delivered* to the public within the new "Longevity Ready" social, economic, and political model. This week's update, in its entirety, provides a clear and complete snapshot of this nascent, integrated, and functional future.

Works cited

1. Vascarta and CUNY Report Preclinical Breakthrough Demonstrating STO-1 Selectively Eliminates Glioblastoma Cells - BioPharma BoardRoom, accessed November 11, 2025, https://www.biopharmaboardroom.com/news/56/3992/vascarta-and-cuny-report-preclinical-breakthrough-demonstrating-sto-1-selectively-eliminates-glioblastoma-cells.html
2. IN SERVICE OF BETTER HEALTH - Milken Institute, accessed November 11, 2025, https://milkeninstitute.org/sites/default/files/2025-08/FHS25-fact-sheet-08132025.pdf
3. Milken Institute International, accessed November 11, 2025, https://milkeninstitute.org/international
4. U.S. Healthcare Archives - Ermer and Suter PLLC, accessed November 11, 2025, https://www.ermersuter.com/category/u-s-healthcare/
5. Table of Contents — June 10, 2025, 122 (23) | PNAS, accessed November 11, 2025, https://www.pnas.org/toc/pnas/122/23
6. Vascarta and CUNY Report Preclinical Breakthrough in Glioblastoma Treatment - BioSpace, accessed November 11, 2025, https://www.biospace.com/press-releases/vascarta-and-cuny-report-preclinical-breakthrough-in-glioblastoma-treatment
7. Cells | An Open Access Journal from MDPI, accessed November 11, 2025, https://www.mdpi.com/journal/cells?amp%3B_utm_from=5e0a18fd0f&wechat=cells
8. Cellular Mechanism Award Archives - Network Science, accessed November 11, 2025, https://networkscience-conferences.researchw.com/tag/cellular-mechanism-award/
9. Probal Banerjee | Author - SciProfiles, accessed November 11, 2025, https://sciprofiles.com/profile/1648310
10. IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways | The EMBO Journal, accessed November 11, 2025, https://www.embopress.org/doi/10.1093/emboj/17.4.1006
11. Novel Taxol-Derivative, STO-1, Induces Selective Anti-Tumor Immunity and Sustained Remission of Glioblastoma Without Triggering Autoimmune Reactions - ResearchGate, accessed November 11, 2025, https://www.researchgate.net/publication/397092768_Novel_Taxol-Derivative_STO-1_Induces_Selective_Anti-Tumor_Immunity_and_Sustained_Remission_of_Glioblastoma_Without_Triggering_Autoimmune_Reactions
12. Novel Taxol-Derivative, STO-1, Induces Selective Anti-Tumor ... - MDPI, accessed November 11, 2025, https://doi.org/10.3390/cells14211703
13. Transdermal & Pre-Clinical Research Hub - Vascarta, accessed November 11, 2025, https://vascarta.com/pre-clinical-research/
14. Autoimmune complications of immunotherapy: pathophysiology and

management | Request PDF - ResearchGate, accessed November 11, 2025, https://www.researchgate.net/publication/340466276_Autoimmune_complications_of_immunotherapy_pathophysiology_and_management
15. Targeting CAR T-Cell Therapy: Molecular Research and Its Future ..., accessed November 11, 2025, https://www.mdpi.com/1422-0067/26/22/10868
16. Klotho, neuroprotection and the biology of aging - Longevity.Technology, accessed November 11, 2025, https://longevity.technology/news/klotho-neuroprotection-and-the-biology-of-aging/
17. klotho neurosciences, inc. - SEC.gov, accessed November 11, 2025, https://www.sec.gov/Archives/edgar/data/1907223/000121390025013279/ea023104l-424b3_klotho.htm
18. Age-related brain changes in mice strike hypothalamus 'hot spot' | The Transmitter, accessed November 11, 2025, https://www.thetransmitter.org/aging/age-related-brain-changes-in-mice-strike-hypothalamus-hot-spot/
19. Recent clinical trials with stem cells to slow or reverse normal aging processes - PMC - NIH, accessed November 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10116573/
20. Latest Articles | PNAS, accessed November 11, 2025, https://www.pnas.org/latest
21. Warming waters herald a submarine eruption | PNAS, accessed November 11, 2025, https://www.pnas.org/doi/abs/10.1073/pnas.2526455122
22. Forecasting weather and health heat impact - PNAS, accessed November 11, 2025, https://www.pnas.org/doi/abs/10.1073/pnas.2525458122
23. Predicting Gene Expression Research Articles - R Discovery, accessed November 11, 2025, https://discovery.researcher.life/topic/predictable-gene-expression/24880648?page=1&topic_name=Predictable%20Gene%20Expression
24. (PDF) Tissue-specific impacts of aging and genetics on gene expression patterns in humans, accessed November 11, 2025, https://www.researchgate.net/publication/364114819_Tissue-specific_impacts_of_aging_and_genetics_on_gene_expression_patterns_in_humans
25. Histopathological Imaging–Environment Interactions in Cancer Modeling - ResearchGate, accessed November 11, 2025, https://www.researchgate.net/publication/332640784_Histopathological_Imaging-Environment_Interactions_in_Cancer_Modeling
26. Mark Gerstein (0000-0002-9746-3719) - ORCID, accessed November 11, 2025, https://orcid.org/0000-0002-9746-3719
27. Ran Meng - Yale School of Medicine, accessed November 11, 2025, https://medicine.yale.edu/profile/ran-meng/
28. PNAS – Explore High-Impact Scientific Research Across Disciplines from One of the World's Most-Cited Journals, accessed November 11, 2025, https://www.pnas.org/
29. In This Issue | PNAS, accessed November 11, 2025, https://www.pnas.org/doi/10.1073/iti4425122

30. Reply to Singer: Strike paper mills at the root - PNAS, accessed November 11, 2025, https://www.pnas.org/doi/10.1073/pnas.2524787122
31. In This Issue - PNAS, accessed November 11, 2025, https://www.pnas.org/doi/abs/10.1073/iti4425122
32. Shifting power asymmetries in scientific teams reveal China's rising leadership in global science | PNAS, accessed November 11, 2025, https://www.pnas.org/doi/10.1073/pnas.2414893122
33. Science and sensitivity in the study of not having sex - PNAS, accessed November 11, 2025, https://www.pnas.org/doi/10.1073/pnas.2523641122
34. Psychological and Cognitive Sciences | Proceedings of the National Academy of Sciences |, accessed November 11, 2025, https://www.pnas.org/psychological-and-cognitive-sciences
35. Milken Institute Future of Health Summit 2025 Explores Innovative and Impactful Ideas to Reimagine Health, accessed November 11, 2025, https://milkeninstitute.org/content-hub/news-releases/milken-institute-future-health-summit-2025-explores-innovative-and-impactful-ideas-reimagine-health
36. Milken Institute Future of Health Summit 2025 Explores Innovative and Impactful Ideas to Reimagine Health | Morningstar, accessed November 11, 2025, https://www.morningstar.com/news/business-wire/20251104442135/milken-institute-future-of-health-summit-2025-explores-innovative-and-impactful-ideas-to-reimagine-health
37. Future of Health Summit 2025 | Milken Institute, accessed November 11, 2025, https://milkeninstitute.org/events/future-health-summit-2025
38. Charting the next wave of growth and innovation in advanced therapies - Deloitte, accessed November 11, 2025, https://www.deloitte.com/us/en/insights/industry/health-care/cell-and-gene-therapies-growth-innovation.html
39. Program | Milken Institute, accessed November 11, 2025, https://milkeninstitute.org/events/future-health-summit-2025/program
40. LONGEVITY READY: - Milken Institute, accessed November 11, 2025, https://milkeninstitute.org/sites/default/files/2025-10/LongevityReadySystemsApproachAgingWell.pdf